Ketamine for Depression in Cancer: Systematic Review Insights

Ketamine's Rapid Antidepressant Effects in Cancer Patients

Depression is a prevalent and serious issue among cancer patients, affecting their quality of life and treatment adherence. Traditional antidepressants can take weeks to become effective, posing a challenge for those needing immediate relief. A recent systematic review, published on May 29, 2026, in OpenAlex, highlights ketamine's potential as a rapid-acting antidepressant for cancer patients. The review, following PRISMA guidelines and registered with PROSPERO (CRD42024603120), suggests that ketamine can alleviate depressive symptoms within hours to days.

Mechanism and Context of Ketamine Use

Ketamine, originally used as an anesthetic, has gained attention for its rapid antidepressant effects. Unlike traditional antidepressants that target serotonin pathways, ketamine acts on the N-methyl-D-aspartate (NMDA) receptor, which may account for its swift action. This mechanism offers a promising alternative for cancer patients, who often experience depression as a comorbidity that can hinder their overall prognosis and treatment outcomes.

Policy and Research Implications

The review analyzed 14 studies, including randomized controlled trials and cohort studies, which collectively support ketamine's efficacy in reducing depressive symptoms and improving anxiety, pain, and quality of life. These findings underscore the need for health policies that incorporate ketamine as a treatment option in oncology settings. However, the review emphasizes the necessity of further research to determine optimal dosing strategies and long-term safety, which are crucial for broader clinical application.

Risks and Unknowns

While ketamine shows promise as a short-term treatment, the review reports short-term side effects such as fatigue, dizziness, and dissociation. Long-term safety data remain limited, raising concerns about potential adverse effects with prolonged use. These gaps highlight the importance of conducting comprehensive studies to evaluate the risks associated with extended ketamine treatment in cancer patients.

Looking Forward

The systematic review positions ketamine as a viable short-term option for managing depression in cancer patients, particularly those with treatment-resistant depression. As the field progresses, researchers and policymakers must prioritize studies that address the long-term implications of ketamine use. Such efforts will be critical in establishing ketamine's role in oncology and ensuring that patients receive safe and effective care.